New treatments and completed trials across every condition — what was tested, what was found, and what it means for patients.
Condition guides
Fallopian tube cancer is rare, accounting for about 1% of gynecologic cancers.
Read the guide →Knee osteoarthritis affects more than 14 million Americans, making it the most common joint disease.
Read the guide →Acute coronary syndrome includes heart attacks and unstable angina — sudden blockages in the heart's arteries.
Read the guide →Ischemic stroke happens when a blood clot blocks flow to part of the brain, killing brain cells within minutes.
Read the guide →Cardiovascular disease remains the leading cause of death worldwide, but death rates have dropped sharply over the past 30 years thanks to statins, blood pressure medications, and improved heart attack care.
Read the guide →Myopia, or nearsightedness, affects about one-third of adults in the United States and is rising worldwide, particularly in children.
Read the guide →Researchers tested delgocitinib cream in 98 adolescents with moderate to severe hand eczema. After 16 weeks, 64% of teens using the cream had clear or almost clear skin, compared to 29% using a placebo cream. The treatment was well tolerated with no serious side effects.
What this means for patients
Delgocitinib cream is FDA-approved for adults with moderate to severe hand eczema. This study shows it works well in teens too, but it is not yet approved for adolescents. If your teen has severe hand eczema, ask your dermatologist whether delgocitinib or similar treatments might be right for them.
Researchers tested tavapadon, a once-daily pill, in 304 people with early Parkinson's disease. After 26 weeks, those taking tavapadon had significantly better movement and daily function scores compared to those on a sugar pill, with side effects mainly including nausea, headache, and dizziness.
Read →Researchers tested an 8-week online program combining talk therapy and gentle exercise for teens with ongoing sickle cell pain. Over 4 in 5 teens reported less pain after completing the program, and the improvement lasted at least 3 months.
Read →Researchers tested a targeted combination therapy called venetoclax-obinutuzumab against traditional chemotherapy in people newly diagnosed with chronic lymphocytic leukemia. More patients on the targeted therapy had no detectable cancer in their blood after treatment.
Read →Scientists tested an online therapy program called ReSeT for children who developed stress symptoms after being hospitalized for injuries like broken bones or burns. Kids who used the program had fewer stress symptoms than those who got usual care, and the benefits lasted at least six months.
Read →The RUBY trial tested reni-cel, a one-time gene editing treatment for patients with severe sickle cell disease who experience frequent painful crises. Researchers modified each patient's own stem cells to reactivate fetal hemoglobin — preventing cells from taking the sickle shape that causes blockages and organ damage.
Read →Military personnel with PTSD received either real or sham magnetic brain stimulation plus intensive therapy. Those who got real stimulation had greater symptom relief that lasted longer—85% still improved at one month versus 59% with sham treatment.
Read →